Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
about
Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.Busulfan in hematopoietic stem cell transplant setting.Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation.Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists.
P2860
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@en
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@nl
type
label
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@en
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@nl
prefLabel
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@en
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@nl
P2093
P1476
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
@en
P2093
Ashwin Kashyap
Borje S Andersson
Daniel Couriel
Hugo Fernandez
John R Wingard
Karl G Blume
Marcos de Lima
Peter F Thall
Richard E Champlin
P304
P356
10.1016/J.BBMT.2003.09.001
P577
2003-11-01T00:00:00Z